This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rietschel, P. Articles by Chapman, P. B. Search for Related Content PubMed PubMed Citation Articles by Rietschel, P. Articles by Chapman, P. B. Social Bookmarking                            What's this?

Variates of Survival in Metastatic Uveal Melanoma

From the Departments of Medicine, Epidemiology and Biostatistics, and Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Paul B. Chapman, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: chapmanp{at}mskcc.org

PURPOSE: The course and outcome of metastatic uveal melanoma are not well described. We evaluated the survival of our patients with metastatic uveal melanoma, described factors that correlated with survival, and evaluated the influence of screening tests on time of detection and survival.

PATIENTS AND METHODS: All patients with metastatic uveal melanoma seen at Memorial Sloan-Kettering Cancer Center between 1994 and 2004 were identified from our database. We recorded date of initial diagnosis, date of metastatic disease, date of last follow-up, site of the first metastasis, how the first metastasis was discovered, treatment, and outcome of therapy.

RESULTS: The estimated median survival of the 119 patients analyzed was 12.5 months; 22% of patients were alive at 4 years. Five variates correlated independently with prolonged survival: Lung/soft tissue as only site of first metastasis, treatment with surgery or intrahepatic therapy, female sex, age younger than 60, and a longer interval from initial diagnosis to metastatic disease. Discovering metastatic disease in asymptomatic patients did not correlate with overall survival; 89% of patients had a single organ as the site of first metastasis. Although liver was the most common site, 39.5% of patients had nonliver sites, most commonly lung, as the first site of metastasis.

CONCLUSION: A substantial subset of patients with metastatic uveal melanoma survive more than 4 years with metastatic disease. Data on variates of survival and site of first metastasis may guide strategies for screening patients, although our data failed to show a survival advantage in discovering asymptomatic metastatic disease.

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Yamamoto, I. Chervoneva, K. L. Sullivan, D. J. Eschelman, C. F. Gonsalves, M. J. Mastrangelo, D. Berd, J. A. Shields, C. L. Shields, M. Terai, et al. High-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal Melanoma Radiology, July 1, 2009; 252(1): 290 - 298. [Abstract] [Full Text] [PDF]

				A. B. Daniels and D. H. Abramson c-KIT in Uveal Melanoma: Big Fish or Red Herring? Arch Ophthalmol, May 1, 2009; 127(5): 695 - 697. [Full Text] [PDF]

				T. Sato, D. J. Eschelman, C. F. Gonsalves, M. Terai, I. Chervoneva, P. A. McCue, J. A. Shields, C. L. Shields, A. Yamamoto, D. Berd, et al. Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor J. Clin. Oncol., November 20, 2008; 26(33): 5436 - 5442. [Abstract] [Full Text] [PDF]

				S. Bakalian, J.-C. Marshall, P. Logan, D. Faingold, S. Maloney, S. Di Cesare, C. Martins, B. F. Fernandes, and M. N. Burnier Jr. Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma Clin. Cancer Res., February 15, 2008; 14(4): 951 - 956. [Abstract] [Full Text] [PDF]

				T. Meir, R. Dror, X. Yu, J. Qian, I. Simon, J. Pe'er, and I. Chowers Molecular Characteristics of Liver Metastases from Uveal Melanoma Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4890 - 4896. [Abstract] [Full Text] [PDF]

				J.-C. A. Marshall, B. F. Fernandes, S. Di Cesare, S. C. Maloney, P. T. Logan, E. Antecka, and M. N. Burnier Jr The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma Carcinogenesis, September 1, 2007; 28(9): 2053 - 2058. [Abstract] [Full Text] [PDF]

				E. S. Gragoudas Proton Beam Irradiation of Uveal Melanomas: The First 30 Years The Weisenfeld Lecture Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4666 - 4673. [Full Text] [PDF]